Starving pancreatic cancer before it has a chance to feast

June 23, 2014, Kansas State University

(Medical Xpress)—Pancreatic cancer's low survival rate gives researchers from The University of Kansas Cancer Center even more reason to find a way to prevent and treat the hard-to-detect cancer. Drs. Snigdha Banerjee, Ph.D., and Sushanta Banerjee, Ph.D., a husband and wife research team at the Kansas City VA Medical Center, are working towards cutting off the growth of pancreatic tumors before they can metastasize throughout the body. Their main target is angiogenesis—or creating new blood vessels from existing ones.

Pancreatic cancer and other cancers can only thrive, grow and spread if they have nutrients from blood, just like other tissues in our bodies. Cancer cells and tumors at first rely on nearby to get what they need to survive, but, as tumors grow, they need to form new vessels. These vessels differ from those in regular tissue, Sushanta explained, which is part of the reason cancer can be so difficult to treat.

"Tumor blood vessels are different than regular blood vessels," said Sushanta. "Tumor vessels are sluggish and leaky, so when we try and treat cancer with drugs they can't easily reach the tumor because the vessels aren't strong."

In previous research, the Banerjees discovered that a particular protein, CCN1, is overexpressed in , which leads to tumor formation. Knowing that this protein could be a key target in treating pancreatic cancer, they sought to understand exactly how it works. In a recent paper published in Scientific Reports (Nature publishing group), they explain how CCN1 signals tumor angiogenesis in pancreatic cancer.

CCN1 promotes new blood vessel growth in both normal and cancer tissues. But CCN1 does something extra when it's secreted by pancreatic tumor cells as opposed to regular cells. It both promotes angiogenesis within the tumor and increased the migration of endothelial cells, which form the inner lining of blood vessels. This migration process is key in the formation of the , according to the National Cancer Institute.

"The tumor cell secretes CCN1 into itself, which is a signal to start angiogenesis," said Snigdha. "So it seems that if you can target CCN1 with a drug, then the will shrink and stop growing."

There is another piece necessary for the pancreatic cancer cell to start forming its own blood vessels - through their research, the Banerjees found that CCN1 is a crucial regulator of SHh, or the "sonic hedgehog" gene. They found that SHh activated by CCN1 also promotes blood vessel formation in the pancreatic cancer cells.

"Both of these components seem to be critical for angiogenesis," said Sushanta.

Understanding this process can lead to better targeted therapies for pancreatic cancer. When the Banerjees knocked down the CCN1 protein using shRNA, very few vessels and capillaries formed under mouse skin. This finding suggests that finding or creating a drug that silences CCN1 could slow down or even stop pancreatic cancer tumors from growing.

Pancreatic cancer is one of the most aggressive cancers. Nearly 40,000 people are estimated to die from pancreatic cancer in 2014 and there will be around 46,000 new cases diagnosed, according to the National Cancer Institute. Only 6.7 percent of those diagnosed with pancreatic cancer will go on to live at least five years.

"The next step would be to find an existing drug that can target the CCN1 protein, or create one," said Snigdha.

Explore further: Some pancreatic cancer treatments may be going after the wrong targets, study finds

Related Stories

Some pancreatic cancer treatments may be going after the wrong targets, study finds

May 22, 2014
New research represents a significant change in the understanding of how pancreatic cancer grows – and how it might be defeated.

Protein inhibits tumor growth

June 19, 2014
Cleveland: A previously unknown variant of an extensively studied protein has been found to inhibit the growth of tumors and slow the development of new blood vessels necessary for cancers to metastasize, according to Cleveland ...

Molecule linked to aggressive pancreatic cancer offers potential clinical advances

May 21, 2014
Mayo Clinic researchers have discovered an enzyme they say is tightly linked to how aggressive pancreatic cancer will be in a patient.

Scientists find potential way to halt pancreatic cancer spread

May 21, 2014
Cancer Research UK scientists have shown how switching off a key protein in pancreatic cells slows the spread of the disease to other tissues, a key step which can mean patients have just weeks to live.

Endoscope with an oxygen sensor detects pancreatic cancer

June 6, 2014
An optical blood oxygen sensor attached to an endoscope is able to identify pancreatic cancer in patients via a simple endoscopic procedure, according to researchers at Mayo Clinic in Florida.

Microfluidic technology reveals potential biomarker for early pancreatic cancer

April 29, 2014
Cancer cells are on the move in the bloodstream in the very early stage of pancreatic cancer, and can be detected before cancer is diagnosed, according to research by the University of Michigan Health System.

Recommended for you

Researchers develop a remote-controlled cancer immunotherapy system

January 15, 2018
A team of researchers has developed an ultrasound-based system that can non-invasively and remotely control genetic processes in live immune T cells so that they recognize and kill cancer cells.

Pancreatic tumors may require a one-two-three punch

January 15, 2018
One of the many difficult things about pancreatic cancer is that tumors are resistant to most treatments because of their unique density and cell composition. However, in a new Wilmot Cancer Institute study, scientists discovered ...

New immunotherapy approach boosts body's ability to destroy cancer cells

January 12, 2018
Few cancer treatments are generating more excitement these days than immunotherapy—drugs based on the principle that the immune system can be harnessed to detect and kill cancer cells, much in the same way that it goes ...

Cancer's gene-determined 'immune landscape' dictates progression of prostate tumors

January 12, 2018
The field of immunotherapy - the harnessing of patients' own immune systems to fend off cancer - is revolutionizing cancer treatment today. However, clinical trials often show marked improvements in only small subsets of ...

FDA approves first drug for tumors tied to breast cancer genes

January 12, 2018
(HealthDay)—The U.S. Food and Drug Administration on Friday approved the first drug aimed at treating metastatic breast cancers linked to the BRCA gene mutation.

Breast cancer gene does not boost risk of death: study

January 12, 2018
Young women with the BRCA gene mutation that prompted actress Angelina Jolie's pre-emptive and much-publicised double mastectomy are not more likely to die after a breast cancer diagnosis, scientists said Friday.


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.